Vicore Pharma is granted orphan drug designation for C21 for the treatment of IPF

2016-08-01

The European Commission has granted orphan drug status for Vicore Pharma’s lead compound C21 for the treatment of idiopathic pulmonary fibrosis (IPF).

The European Commission has granted orphan drug status for Vicore Pharma’s lead compound C21 for the treatment of idiopathic pulmonary fibrosis (IPF). 


The European Commission has adopted the opinion issued by EMA to grant orphan drug status for C21, the lead compound developed by Vicore Pharma, for the treatment of IPF. The approval follows on a positive opinion by the EMA where the authority was particularly impressed with the preclinical effects on the pulmonary hypertension aspects of the disease as demonstrated in models of monocrotaline and bleomycin.

For further information, please contact:

Per Jansson, CEO
Tel: +46 709-17 47 46 or email: per.jansson@vicorepharma.com

Johanna Gräns, Ph.D., Regulatory Coordinator: Tel: +46 73-6509180 or email: johanna.grans@vicorepharma.com 

  • Press release in html format